122851-60-9Relevant articles and documents
TRIAZOLOPYRIDINE COMPOUNDS AND USES THEREOF
-
Paragraph 00161, (2018/04/11)
A compound of Formula (IA), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder: wherein A, R6, R7 and R8 are as defined herein.
Phenethyl nicotinamides, a novel class of NaV1.7 channel blockers: Structure and activity relationship
Kers, Inger,MacSari, Istvan,Csjernyik, Gabor,Nyloef, Martin,Skogholm, Karin,Sandberg, Lars,Minidis, Alexander,Bueters, Tjerk,Malmborg, Jonas,Eriksson, Anders B.,Lund, Per-Eric,Venyike, Elisabet,Luo, Lei,Nystroem, Jan-Erik,Besidski, Yevgeni
, p. 6108 - 6115 (2012/10/30)
The NaV1.7 ion channel is an attractive target for development of potential analgesic drugs based on strong genetic links between mutations in the gene coding for the channel protein and inheritable pain conditions. The (S)-N-chroman-3-ylcarboxamide series, exemplified by 1, was used as a starting point for development of new channel blockers, resulting in the phenethyl nicotinamide series. The structure and activity relationship for this series was established and the metabolic issues of early analogues were addressed by appropriate substitutions. Compound 33 displayed acceptable overall in vitro properties and in vivo rat PK profile.
PYRIDINYL ACETONITRILES
-
Page/Page column 52, (2010/02/09)
The present invention is related to pyridinyl acetonitriles as well as to pharmaceutical formulations containing such pyridinyl acetonitriles. Said pyridinyl acetonitriles are modulators of the protein kinase signalling pathways, particularly the one involving Glycogen Kinase Synthase 3 or JNK. The present invention is furthermore related to methods of preparing pyridinyl acetonitriles. X is a substituted or unsubstituted pyridinyl. G is an unsubstituted or substituted pyrimidinyl or triazinyl.